SenoRx' breast brachytherapy tool:
This article was originally published in Clinica
Executive Summary
The US FDA has given SenoRx 510(k) clearance to market its Multi-Lumen Radiation Balloon Applicator for providing brachytherapy to the surgical margins following lumpectomy for breast cancer. The device uses vacuum to remove excess fluid and to adhere closely to often irregularly shaped lumpectomy cavities in order to deliver precise radiation dosing through multiple seed lumens. "Certain patients who are presently candidates for balloon therapy are currently excluded because of the location of the lesion relative to their breast size," claimed Lloyd Malchow, the Aliso Viejo, California firm's president and CEO. "Our multi-lumen approach offers a solution to this problem."
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.